Immune-Based Therapies for Cytomegalovirus Infection

• Smith KO , RasmussenL: Morphology of cytomegalovirus (salivary gland virus).J. Bacteriol.85 , 1319–1325 (1963).
   PubMed Web of Science ®Google Scholar
• Razonable RR : Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients.Am. J. Health Syst. Pharm.62(8 Suppl. 1) , S7–S13 (2005).
   PubMed Web of Science ®Google Scholar
• Almeida LN , AzevedoRS, AmakuM, MassadE: Cytomegalovirus seroepidemiology in an urban community of Sao Paulo, Brazil.Rev. Saude Publica35(2) , 124–129 (2001).
   PubMed Web of Science ®Google Scholar
• de Ory F , RamirezR, Garcia Comas L, Leon P, Sagues MJ, Sanz JC: Is there a change in cytomegalovirus seroepidemiology in Spain? Eur. J. Epidemiol.19(1) , 85–89 (2004).
   PubMed Web of Science ®Google Scholar
• Colugnati FA , StarasSA, DollardSC, CannonMJ: Incidence of cytomegalovirus infection among the general population and pregnant women in the United States.BMC Infect. Dis.7 , 71 (2007).
   PubMed Web of Science ®Google Scholar
• Compton T , Kurt-JonesEA, BoehmeKW et al.: Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2.J. Virol.77(8) , 4588–4596 (2003).
   PubMed Web of Science ®Google Scholar
• Kijpittayarit S , EidAJ, BrownRA, PayaCV, RazonableRR: Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation.Clin. Infect. Dis.44(10) , 1315–1320 (2007).
   PubMed Web of Science ®Google Scholar
• Cummins NW , DezielPJ, AbrahamRS, RazonableRR: Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation.Transpl. Infect. Dis.11(1) , 20–27 (2009).
   PubMed Web of Science ®Google Scholar
• Fletcher JM , Vukmanovic-StejicM, DunnePJ et al.: Cytomegalovirus-specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion.J. Immunol.175(12) , 8218–8225 (2005).
   PubMed Web of Science ®Google Scholar
• Humar A , MazzulliT, MoussaG et al.: Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients.Am. J. Transpl.5(5) , 1065–1070 (2005).
   PubMed Web of Science ®Google Scholar
• Escobar MR , AllisonMJ, DaltonHP: Etiology and laboratory diagnosis of infectious mononucleosis: II. Cytomegalovirus (CMV) mononucleosis.VA Med. Mon.97(3) , 191–192 (1970).
   PubMedGoogle Scholar
• Razonable RR , EmeryVC: Management of CMV infection and disease in transplant patients. 27–29 February 2004.Herpes11(3) , 77–86 (2004).
   PubMedGoogle Scholar
• Razonable RR , PayaCV: Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.Expert Rev. Anti-infect. Ther.2(1) , 27–41 (2004).
   PubMedGoogle Scholar
• Neuwirth J , GutmanI, HofeldtAJ et al.: Cytomegalovirus retinitis in a young homosexual male with acquired immunodeficiency.Ophthalmology89(7) , 805–808 (1982).
   PubMed Web of Science ®Google Scholar
• Whitley RJ : Congenital cytomegalovirus infection: epidemiology and treatment.Adv. Exp. Med. Biol.549 , 155–160 (2004).
   PubMed Web of Science ®Google Scholar
• Razonable RR , RiveroA, RodriguezA et al.: Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.J. Infect. Dis.184(11) , 1461–1464 (2001).
   PubMed Web of Science ®Google Scholar
• Razonable RR : Cytomegalovirus infection after liver transplantation: current concepts and challenges.World J. Gastroenterol.14(31) , 4849–4860 (2008).
   PubMed Web of Science ®Google Scholar
• Arthurs SK , EidAJ, PedersenRA et al.: Delayed-onset primary cytomegalovirus disease after liver transplantation.Liver Transpl.13(12) , 1703–1709 (2007).
   PubMed Web of Science ®Google Scholar
• Arthurs SK , EidAJ, PedersenRA et al.: Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation.Clin. Infect. Dis.46(6) , 840–846 (2008).
   PubMed Web of Science ®Google Scholar
• Kijpittayarit-Arthurs S , EidAJ, KremersWK et al.: Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients.J. Heart Lung Transpl.26(10) , 1019–1024 (2007).
   PubMed Web of Science ®Google Scholar
• Eid AJ , BakriSJ, KijpittayaritS, RazonableRR: Clinical features and outcomes of cytomegalovirus retinitis after transplantation.Transpl. Infect. Dis.10(1) , 13–18 (2008).
   PubMed Web of Science ®Google Scholar
• Kimberlin DW , LinCY, SanchezPJ et al.: Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial.J. Pediatr.143(1) , 16–25 (2003).
   PubMed Web of Science ®Google Scholar
• Nassetta L , KimberlinD, WhitleyR: Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies.J. Antimicrob. Chemother.63(5) , 862–867 (2009).
   PubMed Web of Science ®Google Scholar
• Whitley RJ , CloudG, GruberW et al.: Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a Phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.J. Infect. Dis.175(5) , 1080–1086 (1997).
   PubMed Web of Science ®Google Scholar
• Jabs DA , GriffithsPD: Fomivirsen for the treatment of cytomegalovirus retinitis.Am. J. Ophthalmol.133(4) , 552–556 (2002).
   PubMed Web of Science ®Google Scholar
• Whitley RJ , JacobsonMA, FriedbergDN et al.: Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society – USA.Arch. Intern. Med.158(9) , 957–969 (1998).
   PubMedGoogle Scholar
• Martin DF , DunnJP, DavisJL et al.: Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society – USA panel.Am. J. Ophthalmol.127(3) , 329–339 (1999).
   PubMed Web of Science ®Google Scholar
• Aberg J , KaplanJE, LibmanH et al.: Primary Care Guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Disease Society of America.Clin. Infect. Dis.49 , 651–681 (2009).
   PubMed Web of Science ®Google Scholar
• Jouan M , SavesM, TubianaR et al.: Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy.AIDS15(1) , 23–31 (2001).
   PubMed Web of Science ®Google Scholar
• Whitcup SM , FortinE, LindbladAS et al.: Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis.J. Am. Med. Assoc.282(17) , 1633–1637 (1999).
   PubMed Web of Science ®Google Scholar
• Asberg A , HumarA, RollagH et al.: Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients.Am. J. Transpl.7(9) , 2106–2113 (2007).
   PubMed Web of Science ®Google Scholar
• Asberg A , HumarA, JardineAG et al.: Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients.Am. J. Transpl.9(5) , 1205–1213 (2009).
   PubMed Web of Science ®Google Scholar
• Razonable RR , PayaCV: Infections and allograft rejection – intertwined complications of organ transplantation.Swiss Med. Wkly135(39–40) , 571–573 (2005).
   PubMed Web of Science ®Google Scholar
• Spector SA , McKinleyGF, LalezariJP et al.: Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group.N. Engl. J. Med.334(23) , 1491–1497 (1996).
   PubMed Web of Science ®Google Scholar
• Wohl DA , KendallMA, AndersenJ et al.: Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.HIV Clin. Trials10(3) , 143–152 (2009).
   PubMed Web of Science ®Google Scholar
• Gane E , SalibaF, ValdecasasGJ et al.: Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group (corrected).Lancet350(9093) , 1729–1733 (1997).
   PubMed Web of Science ®Google Scholar
• Lowance D , NeumayerHH, LegendreCM et al.: Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.N. Engl. J. Med.340(19) , 1462–1470 (1999).
   PubMed Web of Science ®Google Scholar
• Paya C , HumarA, DominguezE et al.: Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.Am. J. Transpl.4(4) , 611–620 (2004).
   PubMed Web of Science ®Google Scholar
• Chandler SH , HandsfieldHH, McDougallJK: Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted disease.J. Infect. Dis.155(4) , 655–660 (1987).
   PubMed Web of Science ®Google Scholar
• Manuel O , PangXL, HumarA, KumarD, DoucetteK, PreiksaitisJK: An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants.J. Infect. Dis.199(11) , 1621–1628 (2009).
   PubMed Web of Science ®Google Scholar
• Gonczol E , PlotkinS: Development of a cytomegalovirus vaccine: lessons from recent clinical trials.Exp. Opin. Biol. Ther.1(3) , 401–412 (2001).
   PubMed Web of Science ®Google Scholar
• Sachs GW , SimmonsRL, BalfourHH Jr: Cytomegalovirus vaccine: persistence of humoral immunity following immunization of renal transplant candidates. Vaccine2(3) , 215–218 (1984).
   PubMedGoogle Scholar
• Plotkin SA , SmileyML, FriedmanHM et al.: Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants.Lancet1(8376) , 528–530 (1984).
   PubMed Web of Science ®Google Scholar
• Brayman KL , DafoeDC, SmytheWR et al.: Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine. Interim results of a randomized controlled trial.Arch. Surg.123(12) , 1502–1508 (1988).
   PubMedGoogle Scholar
• Plotkin SA , StarrSE, FriedmanHM et al.: Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial.Ann. Intern. Med.114(7) , 525–531 (1991).
   PubMed Web of Science ®Google Scholar
• Plotkin SA , HigginsR, KurtzJB et al.: Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients.Transplantation.58(11) , 1176–1178 (1994).
   PubMed Web of Science ®Google Scholar
• Heineman TC , SchleissM, BernsteinDI et al.: A Phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.J. Infect. Dis.193(10) , 1350–1360 (2006).
   PubMed Web of Science ®Google Scholar
• Pass RF , ZhangC, EvansA et al.: Vaccine prevention of maternal cytomegalovirus infection.N. Engl. J. Med.360(12) , 1191–1199 (2009).
   PubMed Web of Science ®Google Scholar
• Sinzger C : Entry route of HCMV into endothelial cells.J. Clin. Virol.41(3) , 174–179 (2008).
   PubMed Web of Science ®Google Scholar
• Wang D , YuQC, SchroerJ, MurphyE, ShenkT: Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells.Proc. Natl Acad. Sci. USA104(50) , 20037–20042 (2007).
   PubMed Web of Science ®Google Scholar
• Snydman DR , WernerBG, Heinze-LaceyB et al.: Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients.N. Engl. J. Med.317(17) , 1049–1054 (1987).
   PubMed Web of Science ®Google Scholar
• Bonaros N , MayerB, SchachnerT, LauferG, KocherA: CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.Clin. Transpl.22(1) , 89–97 (2008).
   PubMed Web of Science ®Google Scholar
• Hodson EM , JonesCA, StrippoliGF, WebsterAC, CraigJC: Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients.Cochrane Database Syst. Rev.18(2) , CD005129 (2007).
   Google Scholar
• Zamora MR , NicollsMR, HodgesTN et al.: Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation.Am. J. Transpl.4(10) , 1635–1642 (2004).
   PubMed Web of Science ®Google Scholar
• Ruttmann E , GeltnerC, BucherB et al.: Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.Transplantation81(10) , 1415–1420 (2006).
   PubMed Web of Science ®Google Scholar
• Solidoro P , DelsedimeL, BergalloM et al.: Combined prophylaxis decreases incidence of CMV-associated pneumonia after lung transplantation.Transpl. Proc.41(4) , 1347–1348 (2009).
   PubMed Web of Science ®Google Scholar
• Nigro G , AdlerSP, La Torre R, Best AM: Passive immunization during pregnancy for congenital cytomegalovirus infection. N. Engl. J. Med.353(13) , 1350–1362 (2005).
   PubMed Web of Science ®Google Scholar
• Eid AJ , BrownRA, LoganW et al.: Kinetics of interferon-g producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lympho-cytes and the risk of CMV viremia after allogeneic hematopoietic stem cell transplantation.Transpl. Infect. Dis. (2009) (In press).
   Google Scholar
• Holtappels R , BohmV, PodlechJ, ReddehaseMJ: CD8 T-cell-based immunotherapy of cytomegalovirus infection: ‘proof of concept‘ provided by the murine model.Med. Microbiol. Immunol.197(2) , 125–134 (2008).
   PubMed Web of Science ®Google Scholar
• Cobbold M , KhanN, PourgheysariB et al.: Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers.J. Exp. Med.202(3) , 379–386 (2005).
   PubMed Web of Science ®Google Scholar
• Micklethwaite KP , ClancyL, SandherU et al.: Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation.Blood112(10) , 3974–3981 (2008).
   PubMed Web of Science ®Google Scholar
• Bao L , DunhamK, StamerM, MulieriKM, LucasKG: Expansion of cytomegalovirus pp65 and IE-1-specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation.Biol. Blood Marrow Transpl.14(10) , 1156–1162 (2008).
   PubMed Web of Science ®Google Scholar
• Li Pira G , IvaldiF, TripodiG, MartinengoM, MancaF: Positive selection and expansion of cytomegalovirus-specific CD4 and CD8 T cells in sealed systems: potential applications for adoptive cellular immunoreconstitution.J. Immunother.31(8) , 762–770 (2008).
   PubMedGoogle Scholar
• Brestrich G , ZwingerS, FischerA et al.: Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy.Am. J. Transpl.9(7) , 1679–1684 (2009).
   PubMed Web of Science ®Google Scholar
• Weinberg A , TierneyC, KendallMA et al.: Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviras therapy.J. Infect. Dis.193(4) , 488–493 (2006).
   PubMed Web of Science ®Google Scholar

▪ Website

• List of vaccine identifiers. www.clinicaltrials.gov
   Google Scholar